Researchers at UT Austin advance in neuropathic pain treatment, caused by nerve damage, with promising molecule identified in mouse trials. Conditions like diabetes, multiple sclerosis, and chemotherapy induce this pain, affecting millions globally. Current medications have limited effectiveness and pose addiction risks. FEM-1689, a non-opioid compound, reduces sensitivity.